[Translation] An open-label, multicenter, single-cohort, post-marketing phase IV to evaluate the efficacy, pharmacodynamics, and safety of the anti-FGF23 antibody KRN23 in Chinese pediatric patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) Research
研究KRN 23治疗对中国儿童XLH患者血磷水平的影响。
[Translation] To investigate the effect of KRN 23 treatment on serum phosphorus levels in Chinese children with XLH.